Lutetium therapy-induced carcinoid crisis: A case report and review of literature

Peptide receptor radionuclide therapy with lutetium (Lu)-labeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastatic neuroendocrine tumors. Some of these patients may present with carcinoid syndrome and it is known that rarely carcinoid crisis can...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2020-12, Vol.16 (Supplement), p.S206-208
Main Authors: Yadav, Sanjay Kumar, Jha, Chandan Kumar, Patil, Shrinivas, Datta, Deepanksha, Mishra, Anjali, Pradhan, P K
Format: Article
Language:English
Subjects:
Carcinoid
Care and treatment
Case reports
Case studies
Diagnosis
Metastasis
Peptides
Radiation therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptide receptor radionuclide therapy with lutetium (Lu)-labeled somatostatin analogs is a promising new tool in the management of patients with inoperable or metastatic neuroendocrine tumors. Some of these patients may present with carcinoid syndrome and it is known that rarely carcinoid crisis can be precipitated by surgical or other interventions in these patients. However, there are anecdotal reports of carcinoid crisis after Lu-labeled peptide therapy. We are reporting our experience of successful management of one such case of carcinoid crisis which was precipitated by Lu therapy.
ISSN:0973-1482
1998-4138
DOI:10.4103/jcrt.JCRT_22_18